Ribomic Company Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan.

The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins.

Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

Ribomic Inc.

Country	Japan
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	24
CEO	Yoshikazu Nakamura

Contact Details

Address: Shirokanedai Usui Building Tokyo, 108-0071 Japan
Phone	81 3 3440 3033
Website	ribomic.com

Stock Details

Ticker Symbol	4591
Exchange	Tokyo Stock Exchange
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3974850004
SIC Code	2836

Key Executives

Name	Position
Yoshikazu Nakamura	Chief Executive Officer